Novavax’s COVID-19 Vaccine Has an Edge Over Rivals, Says 5-Star Analyst

The coronavirus isn’t going away just yet. The number of cases in the US passed 4.5 million, bringing the total number of US deaths to 158K.The need for a vaccine could not be more profound. While the data is alarming, the good news is that with each passing day, a vaccine solution is closer to becoming a reality. There are several candidates in the race hoping to be first to market. B.Riley FBR analyst Mayank Mamtani believes Novavax’s (NVAX) vaccine candidate, NVX-CoV2373, could make its way from the back of the pack to the front.Mamtani said, “While acknowledging the 6-8 …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.